{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:53:20Z","timestamp":1792601600205,"version":"4.5.0"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2022,11,1]]},"abstract":"\n Importance<\/jats:title>\n Unlike for prostate cancer, active surveillance for thyroid cancer has not achieved wide adoption. The parameters by which this approach is feasible are also not well defined, nor is the effect of patient anxiety.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine if expanded size\/growth parameters for patients with low-risk thyroid cancer are viable, as well as to assess for cohort differences in anxiety.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This prospective nonrandomized controlled trial was conducted at a US academic medical center from 2014 to 2021, with mean [SD] 37.1 [23.3]\u2013month follow-up. Of 257 patients with 20-mm or smaller Bethesda 5 to 6 thyroid nodules, 222 (86.3%) enrolled and selected treatment with either active surveillance or immediate surgery. Delayed surgery was recommended for size growth larger than 5 mm or more than 100% volume growth. Patients completed the 18-item Thyroid Cancer Modified Anxiety Scale over time.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Active surveillance.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Cumulative incidence and rate of size\/volume growth.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of the 222 patients enrolled, the median (IQR) age for the study population was 46.8 (36.6-58) years, and 76.1% were female. Overall, 112 patients (50.5%) underwent treatment with active surveillance. Median tumor size was 11.0 mm (IQR, 9-15), and larger tumors (10.1-20.0 mm) comprised 67 cases (59.8%). One hundred one (90.1%) continued to receive treatment with active surveillance, 46 (41.0%) had their tumors shrink, and 0 developed regional\/distant metastases. Size growth of more than 5 mm was observed in 3.6% of cases, with cumulative incidence of 1.2% at 2 years and 10.8% at 5 years. Volumetric growth of more than 100% was observed in 7.1% of cases, with cumulative incidence of 2.2% at 2 years and 13.7% at 5 years. Of 110 patients who elected to undergo immediate surgery, 21 (19.1%) had equivocal-risk features discovered on final pathology. Disease severity for all such patients remained classified as stage I. Disease-specific and overall survival rates in both cohorts were 100%. On multivariable analysis, immediate surgery patients exhibited significantly higher baseline anxiety levels compared with active surveillance patients (estimated difference in anxiety scores between groups at baseline, 0.39; 95% CI, 0.22-0.55;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). This difference endured over time, even after intervention (estimated difference at 4-year follow-up, 0.50; 95% CI, 0.21-0.79;\n P<\/jats:italic>\n \u2009=\u2009.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The results of this nonrandomized controlled trial suggest that a more permissive active surveillance strategy encompassing most diagnosed thyroid cancers appears viable. Equivocal-risk pathologic features exist in a subset of cases that can be safely treated, but suggest the need for more granular risk stratification. Surgery and surveillance cohorts possess oppositional levels of worry, elevating the importance of shared decision-making when patients face treatment equivalence.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT02609685<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2022.3875","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T11:01:28Z","timestamp":1663239688000},"page":"1588","source":"Crossref","is-referenced-by-count":92,"title":["Expanded Parameters in Active Surveillance for Low-risk Papillary Thyroid Carcinoma"],"prefix":"10.1001","volume":"8","author":[{"given":"Allen S.","family":"Ho","sequence":"first","affiliation":[{"name":"Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California"},{"name":"Division of Otolaryngology\u2013Head and Neck Surgery, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungjin","family":"Kim","sequence":"additional","affiliation":[{"name":"Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California"},{"name":"Biostatistics and Bioinformatics Research Center, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Zalt","sequence":"additional","affiliation":[{"name":"Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Melany","sequence":"additional","affiliation":[{"name":"Department of Radiology, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene E.","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiology, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Vasquez","sequence":"additional","affiliation":[{"name":"Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Mallen-St. Clair","sequence":"additional","affiliation":[{"name":"Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California"},{"name":"Division of Otolaryngology\u2013Head and Neck Surgery, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Chen","sequence":"additional","affiliation":[{"name":"Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California"},{"name":"Division of Otolaryngology\u2013Head and Neck Surgery, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Missael","family":"Vasquez","sequence":"additional","affiliation":[{"name":"Division of Otolaryngology\u2013Head and Neck Surgery, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemo","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Welmoed K.","family":"van Deen","sequence":"additional","affiliation":[{"name":"Center for Outcomes Research and Education, Division of Health Sciences Research, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Haile","sequence":"additional","affiliation":[{"name":"Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Daskivich","sequence":"additional","affiliation":[{"name":"Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California"},{"name":"Division of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary S.","family":"Zumsteg","sequence":"additional","affiliation":[{"name":"Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California"},{"name":"Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn D.","family":"Braunstein","sequence":"additional","affiliation":[{"name":"Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California"},{"name":"Division of Endocrinology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy L.","family":"Sacks","sequence":"additional","affiliation":[{"name":"Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California"},{"name":"Division of Endocrinology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"coi220045r1","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMp1604412","article-title":"Worldwide thyroid-cancer epidemic? the increasing impact of overdiagnosis.","volume":"375","author":"Vaccarella","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"coi220045r2","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/cncr.v121.11","article-title":"Increasing diagnosis of subclinical thyroid cancers leads to spurious improvements in survival rates.","volume":"121","author":"Ho","year":"2015","journal-title":"Cancer"},{"issue":"18","key":"coi220045r3","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1001\/jama.2017.4011","article-title":"Screening for thyroid cancer: US Preventive Services Task Force recommendation statement.","volume":"317","author":"Bibbins-Domingo","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"coi220045r4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"issue":"8","key":"coi220045r5","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1001\/jamaoncol.2018.1446","article-title":"Change in diagnostic criteria for noninvasive follicular thyroid neoplasm with papillarylike nuclear features.","volume":"4","author":"Nikiforov","year":"2018","journal-title":"JAMA Oncol"},{"issue":"10","key":"coi220045r7","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1001\/jamaoto.2018.1272","article-title":"Effect of a change in papillary thyroid cancer terminology on anxiety levels and treatment preferences: a randomized crossover trial.","volume":"144","author":"Nickel","year":"2018","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"1","key":"coi220045r8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s00268-009-0303-0","article-title":"An observational trial for papillary thyroid microcarcinoma in Japanese patients.","volume":"34","author":"Ito","year":"2010","journal-title":"World J Surg"},{"issue":"6","key":"coi220045r9","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1007\/s00268-009-0359-x","article-title":"Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes.","volume":"34","author":"Sugitani","year":"2010","journal-title":"World J Surg"},{"issue":"10","key":"coi220045r10","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1001\/jamaoto.2017.1442","article-title":"Natural history and tumor volume kinetics of papillary thyroid cancers during active surveillance.","volume":"143","author":"Tuttle","year":"2017","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"12","key":"coi220045r11","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1089\/thy.2018.0263","article-title":"Active surveillance of low-risk papillary thyroid microcarcinoma: a multi-center cohort study in Korea.","volume":"28","author":"Oh","year":"2018","journal-title":"Thyroid"},{"issue":"3","key":"coi220045r12","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz113","article-title":"Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at a single Italian center.","volume":"105","author":"Molinaro","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"coi220045r13","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1089\/thy.2019.0522","article-title":"Experience with active surveillance of thyroid low-risk carcinoma in a developing country.","volume":"30","author":"Sanabria","year":"2020","journal-title":"Thyroid"},{"issue":"3","key":"coi220045r14","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.juro.2017.11.095","article-title":"Clinically localized prostate cancer: AUA\/ASTRO\/SUO guideline: part I: risk stratification, shared decision making, and care options.","volume":"199","author":"Sanda","year":"2018","journal-title":"J Urol"},{"issue":"1","key":"coi220045r15","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1097\/SLA.0000000000004417","article-title":"Barriers to the use of active surveillance for thyroid cancer: results of a physician survey.","volume":"276","author":"Hughes","year":"2022","journal-title":"Ann Surg"},{"issue":"4","key":"coi220045r16","doi-asserted-by":"publisher","first-page":"e1728","DOI":"10.1210\/clinem\/dgaa942","article-title":"Adoption of active surveillance for very low-risk differentiated thyroid cancer in the United States: a national survey.","volume":"106","author":"Pitt","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"coi220045r17","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1080\/03610920701215639","article-title":"A stepwise AIC method for variable selection in linear regression.","volume":"36","author":"Yamashita","year":"2007","journal-title":"Commun Stat Theory Methods"},{"issue":"11","key":"coi220045r19","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1002\/(ISSN)1097-0142","article-title":"The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with prostate cancer.","volume":"97","author":"Roth","year":"2003","journal-title":"Cancer"},{"issue":"3","key":"coi220045r20","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/rssc.2005.54.issue-3","article-title":"Generalized additive models for location, scale and shape.","volume":"54","author":"Rigby","year":"2005","journal-title":"J R Stat Soc Ser C Appl Stat"},{"issue":"8","key":"coi220045r21","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Worm plot: a simple diagnostic device for modelling growth reference curves.","volume":"20","author":"van Buuren","year":"2001","journal-title":"Stat Med"},{"issue":"2","key":"coi220045r22","first-page":"65","article-title":"A simple sequentially rejective multiple test procedure.","volume":"6","author":"Holm","year":"1979","journal-title":"Scand J Stat"},{"issue":"18","key":"coi220045r23","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1001\/jama.295.18.2164","article-title":"Increasing incidence of thyroid cancer in the United States, 1973-2002.","volume":"295","author":"Davies","year":"2006","journal-title":"JAMA"},{"issue":"5","key":"coi220045r24","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1001\/archoto.2010.55","article-title":"Thyroid cancer survival in the United States: observational data from 1973 to 2005.","volume":"136","author":"Davies","year":"2010","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"10","key":"coi220045r25","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1089\/thy.2019.0060","article-title":"Mortality risk of nonoperative papillary thyroid carcinoma: a corollary for active surveillance.","volume":"29","author":"Ho","year":"2019","journal-title":"Thyroid"},{"issue":"8","key":"coi220045r26","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1089\/thy.2016.0073","article-title":"T1a versus T1b differentiated thyroid cancers: do we need to make the distinction?","volume":"26","author":"Anderson","year":"2016","journal-title":"Thyroid"},{"issue":"1","key":"coi220045r27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1089\/thy.2018.0462","article-title":"Active surveillance for T1bN0M0 papillary thyroid carcinoma.","volume":"29","author":"Sakai","year":"2019","journal-title":"Thyroid"},{"issue":"30","key":"coi220045r28","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1200\/JCO.2016.67.7419","article-title":"Prevalence of differentiated thyroid cancer in autopsy studies over six decades: a meta-analysis.","volume":"34","author":"Furuya-Kanamori","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi220045r29","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/jamaoto.2014.1","article-title":"Current thyroid cancer trends in the United States.","volume":"140","author":"Davies","year":"2014","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"11","key":"coi220045r30","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1089\/thy.2012.0043","article-title":"The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension.","volume":"22","author":"Randolph","year":"2012","journal-title":"Thyroid"},{"issue":"5","key":"coi220045r31","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1001\/jamaoncol.2019.6851","article-title":"Incidence and mortality risk spectrum across aggressive variants of papillary thyroid carcinoma.","volume":"6","author":"Ho","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"coi220045r32","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.surg.2017.03.028","article-title":"Estimation of the lifetime probability of disease progression of papillary microcarcinoma of the thyroid during active surveillance.","volume":"163","author":"Miyauchi","year":"2018","journal-title":"Surgery"},{"issue":"6","key":"coi220045r33","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1001\/jamaoto.2020.0368","article-title":"Association of patient age with progression of low-risk papillary thyroid carcinoma under active surveillance: a systematic review and meta-analysis.","volume":"146","author":"Koshkina","year":"2020","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"1","key":"coi220045r34","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1089\/thy.2015.0178","article-title":"A clinical framework to facilitate risk stratification when considering an active surveillance alternative to immediate biopsy and surgery in papillary microcarcinoma.","volume":"26","author":"Brito","year":"2016","journal-title":"Thyroid"},{"issue":"2","key":"coi220045r35","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1089\/thy.2020.0330","article-title":"Indications and strategy for active surveillance of adult low-risk papillary thyroid microcarcinoma: consensus statements from the Japan Association of Endocrine Surgery Task Force on Management for Papillary Thyroid Microcarcinoma.","volume":"31","author":"Sugitani","year":"2021","journal-title":"Thyroid"},{"issue":"5","key":"coi220045r37","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.eururo.2012.01.050","article-title":"Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades.","volume":"61","author":"Epstein","year":"2012","journal-title":"Eur Urol"},{"issue":"15","key":"coi220045r38","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer.","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"coi220045r39","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1001\/jamaoncol.2018.5321","article-title":"Parallels between low-risk prostate cancer and thyroid cancer: a review.","volume":"5","author":"Ho","year":"2019","journal-title":"JAMA Oncol"},{"issue":"7","key":"coi220045r40","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1089\/thy.2019.0592","article-title":"A prospective mixed-methods study of decision-making on surgery or active surveillance for low-risk papillary thyroid cancer.","volume":"30","author":"Sawka","year":"2020","journal-title":"Thyroid"},{"issue":"3","key":"coi220045r41","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.surg.2021.03.056","article-title":"Presence of TERT \u00b1 BRAF V600E mutation is not a risk factor for the clinical management of patients with papillary thyroid microcarcinoma.","volume":"170","author":"Lee","year":"2021","journal-title":"Surgery"},{"key":"coi220045r6","volume-title":"AJCC Cancer Staging Manual","author":"Tuttle","year":"2017","edition":"8th ed"},{"key":"coi220045r18","author":"Bastien"},{"key":"coi220045r36","unstructured":"National Comprehensive Cancer Network Guidelines. Prostate cancer (version 1.2022). Accessed April 1, 2022. https:\/\/www.nccn.org\/guidelines\/guidelines-process\/transparency-process-and-recommendations\/GetFileFromFileManager?fileManagerId=12813"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2796440\/jamaoncology_ho_2022_oi_220045_1668658003.42998.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T11:05:00Z","timestamp":1668683100000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2796440"}},"subtitle":["A Nonrandomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2022.3875","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,1]]}}}